Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

September 30, 2005

Conditions
Constipation
Interventions
DRUG

Tegaserod and Polyethylene Glycol 3350

Trial Locations (14)

23294

National Clinical Research, Inc, Richmond

23454

East Coast Clinical Research, Virginia Beach

33486

Clinical Trial Management of Boca Raton, Inc., Boca Raton

37076

Associates in Gastroenterology, Hermitage

45305

Midwest Clinical Research, Bellbrook

67124

Health Science Center, Pratt

68134

Heartland Clinical Research, Inc, Omaha

77566

R/D Clinical Research, Inc., Lake Jackson

85201

Central Phoenix Medical Clinic, LLC, Phoenix

85712

Adobe Gastroenterology, PC, Tucson

85739

Harmony Clinical Research, Oro Valley

90620

Associated Pharmaceutical Research Center, Inc, Buena Park

02215

Beth Israel Deacon Medical Center, Boston

08402

MBS Clinical Research, LLC, Margate City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00171522 - Preference of Tegaserod vs. PEG 3350 in Patients With Constipation | Biotech Hunter | Biotech Hunter